- Home
- FNLC vs AVTX Comparison
FNLC vs AVTX Comparison
Compare FNLC & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FNLC | AVTX |
|---|---|---|
| Founded | 1864 | 2011 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 306.9M | 248.3M |
| IPO Year | 1995 | 2015 |
Fundamental Metrics
Financial Performance| Metric | FNLC | AVTX |
|---|---|---|
| Price | $29.50 | $15.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $34.50 |
| AVG Volume (30 Days) | 15.8K | ★ 374.7K |
| Earning Date | 04-22-2026 | 04-20-2026 |
| Dividend Yield | ★ 5.12% | N/A |
| EPS Growth | N/A | ★ 81.66 |
| EPS | ★ 2.16 | N/A |
| Revenue | N/A | ★ $27,813,137.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.40 | ★ N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $22.11 | $3.39 |
| 52 Week High | $30.33 | $20.72 |
Technical Indicators
Market Signals| Indicator | FNLC | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.75 | 48.09 |
| Support Level | $28.88 | $13.78 |
| Resistance Level | $29.71 | $14.81 |
| Average True Range (ATR) | 0.72 | 1.15 |
| MACD | 0.02 | 0.11 |
| Stochastic Oscillator | 64.29 | 52.13 |
Price Performance
Historical ComparisonAbout FNLC First Bancorp Inc (ME)
First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services including deposit accounts and consumer, commercial and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).